Relmada Therapeutics, Inc.
General ticker "RLMD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $269.9M (TTM average)
Relmada Therapeutics, Inc. follows the US Stock Market performance with the rate: 37.3%.
Estimated limits based on current volatility of 2.1%: low 4.31$, high 4.50$
Factors to consider:
- Total employees count: 20 (+42.9%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing risks, Intellectual property risks, Commercialization failure
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.78$, 5.19$]
- 2026-12-31 to 2027-12-31 estimated range: [1.26$, 3.68$]
Financial Metrics affecting the RLMD estimates:
- Positive: with PPE of -3.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -25.45 <= 0.28
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 92.03 > 63.63
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: -0.14 < Industry inventory ratio change (median), % of 0
Short-term RLMD quotes
Long-term RLMD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $103.70MM | $83.89MM | $59.10MM |
| Operating Income | $-103.70MM | $-83.89MM | $-59.10MM |
| Non-Operating Income | $4.91MM | $3.91MM | $1.72MM |
| R&D Expense | $54.81MM | $46.18MM | $26.88MM |
| Income(Loss) | $-98.79MM | $-79.98MM | $-57.39MM |
| Net Income(Loss)* | $-98.79MM | $-79.98MM | $-57.39MM |
| Stockholders Equity | $85.36MM | $35.52MM | $86.51MM |
| Assets | $97.55MM | $45.82MM | $94.00MM |
| Operating Cash Flow | $-51.66MM | $-51.76MM | $-45.79MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $50.45MM | $51.56MM | $-48.14MM |
| Financing Cash Flow | $-0.10MM | $-0.04MM | $93.56MM |
| Earnings Per Share** | $-3.28 | $-2.65 | $-1.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.